Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015672 (
fatigue
)
51,768
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An open study was carried out in 30 children with seasonal allergic rhinitis to evaluate the efficacy and tolerance of treatment with a dexbrompheniramine maleate (1.5 mg/5 ml) and pseudoephedrine sulphate (30 mg/5 ml) syrup formulation ('Disophrol' Syrup). Each patient was given 2.5 to 5 ml 4-times daily during the 14-day study period. Relief from signs and symptoms associated with
seasonal rhinitis
was evaluated on Days 7 and 14 of therapy. By Day 7, 5 patients were considered cured, 22 showed marked improvement and 3 patients had improved. At the Day 14 evaluation, 27 patients had complete clearing of signs and symptoms, 2 patients showed a marked improvement while the remaining patient was considered a treatment failure. Body weight and vital signs remained unaffected. Incidence of adverse reactions was limited to one occurrence of extreme
fatigue
, which did not necessitate termination of therapy.
...
PMID:An antihistamine/decongestant formulation ('Disophrol' Syrup) for relief of symptoms in children with seasonal rhinitis. 613 33
Histamine H1 receptor antagonists, or antihistamines, are very effective for treatment of various allergic disorders such as
seasonal rhinitis
and urticaria. Sometimes antihistamines induce sedative CNS side effects that might result in dangerous traffic accidents. That is why a lack of sedation is important for development of new antihistamines. It is clear that all antihistamines have a potential to produce subjective (sleepiness,
fatigue
etc.) and objective sedation (impaired performance), dependent on the histaminergic mechanisms involved in the control of arousal. We have proposed the usefulness of H1 receptor occupancy measurement with Positron Emission Tomography (PET) using 11C-doxepin as a tracer. The PET measurement is currently included as one of the three major factors defined by the international Consensus Group on New Generation Antihistamines (CONGA) for evaluation of antihistamines: 1) incidence of subjective sleepiness, 2) objective and psychomotor functions, and 3) PET measurement of H1 receptor occupancy. Merit of PET measurement is that we can directly calculate the receptor occupancy for each separate drug while the former two should be discussed based on the difference between placebo and active placebo. PET will be used more actively in the development of various new drugs in future.
...
PMID:[A potential of positron emission tomography in the drug development of non-sedative antihistamines]. 1472 29